Press Releases | Alexion Pharmaceuticals, Inc

About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
- North America
  - Canada
  - USA
- Latin America
  - Argentina
  - Brazil
  - Colombia
  - Mexico
- Europe, the Middle East & Africa
  - Alexion Europe
  - Belgium
  - Denmark
  - France
  - Germany
  - Ireland
  - Italy
  - Netherlands
  - Norway
  - Russia
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - UAE
  - UK
- Asia Pacific
  - Australia
  - China
  - India
  - Japan
Investors
News
Contact

Home
»
Newsroom
»
Press Releases

Press Releases

All News Releases

New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
May 3, 2019
HTML PDF
Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
April 26, 2019
HTML PDF
Alexion Reports First Quarter 2019 Results
April 25, 2019
HTML PDF
Alexion to Report First Quarter Results on Thursday, April 25, 2019
April 12, 2019
HTML PDF
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
March 20, 2019
HTML PDF
Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
March 20, 2019
HTML PDF
Alexion to Present at the Cowen 39th Annual Health Care Conference
March 5, 2019
HTML PDF
Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day
February 28, 2019
HTML PDF
FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
February 22, 2019
HTML PDF
Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 21, 2019
HTML PDF